January 11, 2022 By mahmod Adjuvant therapy in HER2-positive breast cancer trastuzumab 6 vs 12 months role of pertuzumab/niratinib Read More
January 11, 2022 By mahmod Adjuvant hormonal therapy what is the optimal duration, duration of LHRH-analougues Lobular breast cancer N1 disease/molecular tools Read More
January 11, 2022 By mahmod Triple negative breast cancer (Non-metastatic): Neoadjuvant immunetherapy/ platinum Postneoadjuvant therapy, PARPi in BRCA mutant Read More
January 11, 2022 By mahmod HR-positive/HER2-negative breast cancer OS with CDK4-6 inhibitors: impact on treatment selection Alpelisib vs. everolimus in 2nd line Early progression after CDK4-6i: chemotherapy vs hormonal therapy Visceral crisis: duration of chemotherapy, role of maintenance hormonal therapy? Read More
January 11, 2022 By mahmod Advanced HER2-positive breast cancer Position of ADC Can we use ADC after another ADC treatment sequence Hormonal therapy+antiHER2 in 1st line Read More
January 11, 2022 By mahmod Triple negative breast cancer Platinum vs PARPi/ can we use one after the other? can we use PARPi beyond BRCA1/2 mutations PARPi in1st line or later lines Immune therapy: Pembro vs atezolizumab in 1st line Can we use immunetherapy in 2nd line after chemotherapy /PARPi Read More